BlossomHill Therapeutics market cap: $495.545 M

Biotechnology: Pharmaceutical Preparations, ranked by market cap

#209Prelude TherapeuticsPRLD$529.1M
#210EvommuneEVMN$508.8M
#211BlossomHill TherapeuticsBLSM$495.5M
#212Relmada TherapeuticsRLMD$493.9M
#213RezoluteRZLT$490.1M

Insiders buying

6 open-market purchases by officers and directors of BlossomHill Therapeutics, worth $25.2M. Grants and option exercises are excluded.

ORBIMED ADVISORS LLC, OrbiMed Capital GP VIII LLC$10.0M
625,000 shares at $16.00 on 10 Aug 2026 · filed 12 Aug 2026
Carl L. Gordon$10.0M
625,000 shares at $16.00 on 10 Aug 2026 · filed 12 Aug 2026
Bihua Chen, Cormorant Asset Management, LP, Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund III LP, Cormorant Private Healthcare Fund V LP, Cormorant Private Healthcare Fund VI, LP$5.00M
312,500 shares at $16.00 on 10 Aug 2026 · filed 10 Aug 2026
John P. Schmid$96.0K
6,000 shares at $16.00 on 10 Aug 2026 · filed 10 Aug 2026
Vincent Paul LiptakGeneral Counsel$74.7K
4,700 shares at $15.89 on 7 Aug 2026 · filed 10 Aug 2026
Jason A. KeyesChief Financial Officer$11.2K
700 shares at $16.00 on 10 Aug 2026 · filed 10 Aug 2026

Where these numbers come from

Share counts and financials for BlossomHill Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 21 Aug 2026. Read the methodology.